多发性硬化症患者的死亡率和死亡原因:芬兰全国范围的注册研究
Katariina Kuutti1,2, Sini M Laakso3,4, Matias Viitala5,6
1Department of Neurology, Turku University Hospital, Turku, Finland. katarha@utu.fi.
Journal of neurology
|May 2, 2025
概括
多发性硬化症 (pwMS) 患者的过度死亡率已经下降,但预期寿命仍然减少了7年. 在治疗时代的早期诊断与pwMS死亡风险较低相关.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 有限的基于人口的纵向数据存在于多发性硬化症 (pwMS) 患者的死亡率和死亡原因 (COD).
- 本研究通过使用全国注册数据,检查芬兰pwMS中所有原因和特定原因死亡率来解决数据的稀缺问题.
研究的目的:
- 调查芬兰多发性硬化症 (pwMS) 患者全因和因特定死亡率的趋势.
- 确定诊断时代对死亡风险的影响,并确定pwMS的特定死亡原因.
主要方法:
- 利用芬兰国家卫生登记册,识别了1971年至2019年间诊断的16602名pwMS患者.
- 计算了标准化死亡率 (SMR),过度死亡率 (EDR) 和预期寿命,通过注册链接分析死亡原因 (COD).
主要成果:
- 标准化死亡率 (SMRs) 从3.07 (1980-1999) 下降到2.18 (2000-2020). 在美国,死亡率从3.07 (1980-1999) 下降到2.18 (2000-2020).
- 预期寿命缩短了7年;多发性硬化症 (MS) 是51.2%的病例 (2000-2020) 的潜在死亡原因.
- 胃肠道,呼吸道和血管疾病的死亡率增加. 1996-2005年的诊断显示死亡风险明显降低 (HR 0.49).
结论:
- 在过去的40年里,芬兰pwMS的过度死亡率显著下降.
- 对于pwMS的预期寿命仍然减少了大约7年,MS是最常见的潜在死亡原因.
- 在治疗时代 (1996-2005年) 诊断的个体的死亡风险较低,突出显示了MS治疗进步的影响.
相关概念视频
Introduction To Survival Analysis
150
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
150
Actuarial Approach
50
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
50
Kaplan-Meier Approach
74
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
74
Assumptions of Survival Analysis
81
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
81
Comparing the Survival Analysis of Two or More Groups
113
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
113
Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315


